Carregant...
SAT-330 Preclinical Screen of Patient CRPC Tumors Shows Sensitivity to Bromodomain Inhibitors Includes AR-null and Neuroendocrine Disease
Castration-resistant prostate cancer (CRPC) remains a lethal disease despite the introduction of second generation androgen receptor (AR) directed therapies. Resistance to AR directed therapies, such as abiraterone and enzalutamide, emerges through diverse alterations in the AR pathway or transition...
Guardat en:
| Publicat a: | J Endocr Soc |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Endocrine Society
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6551945/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-330 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|